<DOC>
	<DOCNO>NCT00899678</DOCNO>
	<brief_summary>The purpose study evaluate safety , efficacy , pharmacokinetics , immunogenicity certolizumab pegol treatment pediatric subject , age 6 17 , moderately severely active Crohn 's disease . The target enrollment 160 subject .</brief_summary>
	<brief_title>The Use Certolizumab Pegol Treatment Active Crohn 's Disease Children Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Subjects active Crohn 's Disease ( CD ) confirm 3 month prior Screening Subjects Pediatric Crohn 's Disease Activity Index ( PCDAI ) score &gt; 30 Week 0 Subjects age 6 17 , inclusive , prior baseline dose Subjects must weigh &gt; 20 kg ( 44 lb ) Subjects must normal Electrocardiogram ( ECG ) medically relevant abnormality assess investigator Subjects must meet Tuberculosis ( TB ) screen criteria Subjects take corticosteroid , antibiotic analgesic must stable dosing , define , one week Subjects score &gt; 5 perirectal disease item PCDAI Baseline Subjects active enterocutaneous fistula within 3 month prior Baseline Subjects nonenterocutaneous fistula , sign symptoms bowel obstruction short bowel syndrome Subjects functional colostomy ileostomy Subjects surgical bowel resection within 6 month prior Baseline may plan resection enrol study Subjects clinical suspicion intraabdominal abscess Subjects positive stool result enteric pathogen and/or parasite Subject receive investigational biological therapy ( within outside clinical trial ) within 12 week prior Screening dose clinical trial use non biological therapy within 4 week prior Screening Subjects lose response another Tumor Necrosis Factor ( TNF ) agent Subjects may use another TNF agent within 12 week Screening Visit Subjects prior exposure natalizumab Subjects receive mycophenolate thalidomide within 4 week prior Screening Subjects receive cyclosporin tacrolimus within 6 month prior Screening Subjects receive parenteral corticosteroid within 2 week prior Screening Subjects receive corticosteroid corticotrophin indication CD within 2 week Screening Subject current recent history ( within 6 month prior Screening ) significant severe renal , hepatic , hematological , gastrointestinal ( CD ) , endocrine , pulmonary , cardiac , neurological , cerebral disease include blood dyscrasia ( eg , pancytopenia , aplastic anemia ) , demyelinate disease ( eg , multiple sclerosis , myelitis , optic neuritis ) , ischemic heart disease Subjects current sign symptom indicate recent chronic infection ( include herpes zoster ) Subject negative test Immunoglobulin G ( IgG ) Varicella zoster ( chicken pox ) Subjects complete primary vaccination series , plan live vaccine administer study period 3 month last dose study drug Subject history TB positive chest xray suggestive TB Subjects know concurrent viral hepatitis Acquired Immune Deficiency Syndrome ( AIDS ) know Human Immunodeficiency Virus ( HIV ) infection Subjects concurrent malignancy history malignancy , exclude treat squamous cell carcinoma skin Subject concurrent bowel dysplasia history bowel dysplasia 5 year prior Screening Subjects history lymphoproliferative disorder include lymphoma sign symptom suggestive lymphoma time</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Certolizumab Pegol</keyword>
	<keyword>Cimzia Â®</keyword>
	<keyword>Crohn 's Disease</keyword>
</DOC>